the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome

the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome

The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization

Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to affect more than 5% of the population and is associated with chronically elevated serum androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive disease during pregnancy,and preterm birth,which is partially related with the hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro fertilization/Intracytoplasmic sperm injection.

Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.

Inclusion Criteria: diagnosed polycystic ovary syndrome patients according to Rotterdam criteria with hyperandrogenism and/or clinical hyperandrogenic manifestations no other oral contraceptives treatment for at least 3 months before this experiment no any other assisted reproductive therapy accompanied with fallopian tube and/or male factors normal hepato-/nephro- function Exclusion Criteria: oral contraceptive pills contraindications, eg.Deep Venous Thrombosis smoking, drunk exclude other infertile factors, eg.endometriosis, abnormal thyroid function, etc.